A Chimeric Oncolytic Virus and T Cell for Cancer Immunotherapy
An innovative method known as ONCOTECH has been developed by researchers to physically attach oncolytic adenoviruses to T-cell surfaces through the interaction of antigens and receptors. To accomplish this, the viruses, which encode a Cas9 system targeting immune checkpoint inhibitor genes, are encased in cell membranes that bear T-cell-specific antigens and delivered intravenously into tumors. …